Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

Lack of grey matter linked to schizophrenia and bipolar disorder

A research study led by scientists from the Gregorio Marañón University Hospital in Madrid and the Network of Centres for Biomedical Research in Mental Health Networks (CIBERSAM) shows that adolescents experiencing a first outbreak of psychosis have lower levels of grey matter in their brains than healthy teenagers. Strangely, this change was seen in patients suffering from various psychoses, including bipolar illness and schizophrenia.

19 Jan 2009

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA), the Department of Justice announced today.

19 Jan 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.

14 Dec 2008

Parkinson's disease can also affect changes in thought, behavior and judgment

Parkinson's disease affects 6.3 million people worldwide. While the disease is recognized for its profound effects on movement, up to 40 percent of Parkinson's disease patients also develop changes in thought, behavior and judgment.

14 Dec 2008

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

AstraZeneca and Targacept, Inc. havey announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

10 Dec 2008

New study focuses on adolescents and young adults at risk for psychosis

Emory University in Atlanta is playing a key role in the largest, most comprehensive study ever funded by the National Institute of Mental Health (NIMH) of adolescents and young adults at risk for developing a psychotic disorder.

12 Nov 2008

Research looks at differential rates of psychoses by ethnicity

Researchers examining the occurrence of psychoses among migrant groups have shown a raised incidence for all black and ethnic minority subgroups compared with white British counterparts, and reveal that the risk of psychoses for first and second generations varies by ethnicity.

5 Nov 2008

Rates of psychosis higher among minority groups in Britain

Both first- and second-generation immigrants to the United Kingdom appear to have a higher risk of psychoses than white British individuals, according to a report in the November issue of Archives of General Psychiatry , one of the JAMA/Archives journals.

4 Nov 2008

Worries over test for mad cow disease

A new test to screen blood for the incurable human form of mad cow disease could be available within 18 months, but it has raised concerns.

21 Oct 2008

Drugs to treat ADHD should be a last resort

According to new guidelines in Britain on attention deficit hyperactivity disorder (ADHD), drugs should be the last resort in treating the disorder and parents need to learn how to cope with their child's unruly behaviour.

24 Sep 2008

Older antipsychotic drugs as effective, offer fewer side effects in children than newer drugs, study finds

The two most frequently prescribed antipsychotic drugs for children and adolescents offer no additional benefit and are more likely to cause side effects than an older, less costly medication, according to a National Institute of Mental Health study published on Monday, the New York Times reports.

16 Sep 2008

New cannabis-like drugs could block pain without affecting brain

A new type of drug could alleviate pain in a similar way to cannabis without affecting the brain, according to a new study published in the journal Pain on Monday 15 September.

15 Sep 2008

FDA approves tetrabenazine for Huntington's disease

The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.

17 Aug 2008

Oestrogen - a beneficial addition to treatment of schizophrenia in women

Australian scientists have found that women suffering from schizophrenia were less likely to suffer hallucinations or delusions, when the hormone oestrogen was added to their treatment.

4 Aug 2008

Genetic change in dopamine transporter supports a role for dopamine signaling in ADHD

A genetic change in the dopamine transporter - one of the brain's dopamine-handling proteins - makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in The Journal of Neuroscience.

9 Jul 2008